Neuroendocrinology of Aging

Brocklehurst's Textbook of Geriatric Medicine and Gerontology

Volumn , Issue , 2010, Pages 163-169

  Brinton, Roberta Diaz ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863676316     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6231-8.10027-3     Document Type: Chapter

References (76)

1. Finch C.E. Aging: A Natural History 1995, WH Freeman and Co, New York, Scientific American Library.
2. Morrison J.H., Brinton R.D., Schmidt P.J., et al. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 2006, 26:10332-10348.
3. Bastian L.A., Smith C.M., Nanda K., et al. Is this woman perimenopausal?. JAMA 2003, 289:895-902.
4. Buckler H.M., Anderson D.C. The perimenopausal state and incipient ovarian failure. Treatment of the Postmenopausal Woman-Basic and Clinical Aspects 1996, Lippincott-Raven, Philadelphia. R. Lobo (Ed.).
5. Burger H.G., Hale G.E., Dennerstein L., et al. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008, 15:603-612.
6. Soules M.R., Sherman S., Parrott E., et al. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril 2001, 76:874-878.
7. Longcope C. The endocrinology of the menopause. Treatment of the Postmenopausal Woman-Basic and Clinical Aspects 1996, Lippincott-Raven, Philadelphia. R.A. Lobo (Ed.).
8. Brann D.W., Mahesh V.B. The aging reproductive neuroendocrine axis. Steroids 2005, 70:273-283.
9. Burger H., Woods N.F., Dennerstein L., et al. Nomenclature and endocrinology of menopause and perimenopause. Expert Rev Neurother 2007, 7(11 Suppl):S35-S43.
10. Chen S., Nilsen J., Brinton R.D., et al. Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: therapeutic implications. Endocrinology 2006, 147:5303-5313.
11. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med 2006, 355:2338-2347.
12. Alexander J.L., Burger H., Dennerstein L., et al. Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. Expert Rev Neurother 2007, 7(11 Suppl):S115-S137.
13. Cranney A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23:570-578.
14. Riggs B.L., et al. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Rev 2002, 23:279-302.
15. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005, 353:595-603.
16. Papapoulos S., Makras P. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2008, 4:514-523.
17. Lobo R.A. Treatment of the postmenopausal woman: where we are today. Treatment of the Postmenopausal Woman-Basic and Clinical Aspects 1996, Lippincott-Raven, Philadelphia. R.A. Lobo (Ed.).
18. Utian W.H., et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008, 15:584-602.
19. Kronenberg F. Hot flashes. Treatment of the Postmenopausal Woman-Basic and Clinical Aspects 1996, Lippincott-Raven, Philadelphia. R.A. Lobo (Ed.).
20. Shoupe D., Mishell Daniel R, et al. Contraindications to hormone replacement. Treatment of the Postmenopausal Woman-Basic and Clinical Aspects 1996, Lippincott-Raven, Philadelphia. R.A. Lobo (Ed.).
21. Zhao L., Brinton R.D. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother 2007, 7:1549-1564.
22. Zhao L., O'Neill K., Brinton R.D., et al. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res Brain Res Rev 2005, 49:472-493.
23. Insights B. The women's health outlook to 2008. In Business Insights Healthcare2003.
24. Zhao L., Brinton R.D. Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. J Med Chem 2005, 48:3463-3466.
25. Zhao L., Jin C., Mao Z., et al. Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator-a hybrid structure of 17beta-estradiol and vitamin E in hippocampal neurons. J Med Chem 2007, 50:4471-4481.
26. Yaffe K., Lindquist K., Sen S., et al. Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the health ABC study. Neurobiol Aging 2007, 28:171-178.
27. Yaffe K., Lui L-Y., Grady D., et al. Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. Biol Psychiatry 2002, 51:677-682.
28. Resnick S.M., Henderson V.W. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002, 288:2170-2172.
29. Brinton R.D. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann NY Acad Sci 2005, 1052:57-74.
30. Brinton R.D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008, 31(10):529-537.
31. Rocca W.A., Bower J.H., Maraganore D.M., et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007, 69:1074-1083.
32. Rocca W.A., Bower J.H., Maraganore D.M., et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008, 70:200-209.
33. Rocca W.A., Grossardt B.R., Geda Y.E., et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008, 15(6):1050-1059.
34. Rocca W.A., Grossardt B.R., Geda Y.E., et al. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008, 5:257-260.
35. Rocca W.A., Bower J.H., Maraganore D.M., et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006, 7:821-828.
36. Rossouw J., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465-1477.
37. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women's health initiative memory study. JAMA 2004, 291:2947-2958.
38. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 2003, 289:2651-2662.
39. Brinton R.D. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev 2008, 60:1504-1511.
40. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine Rev 2005, 26:833-876.
41. Bhasin S., Wu F. Making a diagnosis of androgen deficiency in adult men: what to do until all the facts are in?. Nat Clin Pract Endocrinol Metab 2006, 2:529.
42. Handelsman D.J., Liu P.Y. Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab 2005, 16:39-45.
43. Perheentupa A., Huhtaniemi I. Does the andropause exist?. Nat Clin Pract Endocrinol Metab 2007, 3:670-671.
44. Morley J.E., Perry H.M. Andropause: an old concept in new clothing. Clin Geriatr Med 2003, 19:507-528.
45. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:1995-2010.
46. Khosla S., Amin S., Orwoll E., et al. Osteoporosis in men. Endocrine Rev 2008, 29:441-464.
47. Pike C.J., Nguyen T.V., Ramsden M., et al. Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav 2008, 53:693-705.
48. Gao W., Dalton J.T. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?. Mol Interv 2007, 7:10-13.
49. Segal S., Narayanan R., Dalton J.T., et al. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs 2006, 15:377-387.
50. Cummings D.E., Kumar N., Bardin C.W., et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998, 83(12):4212-4219.
51. Noe G., et al. Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. Hum Reprod 1999, 14(9):2200-2206.
52. Sundaram K., et al. 7 alpha-methyl-19-nortestosterone: an ideal androgen for replacement therapy. Rec Prog Horm Res 1994, 49:373-376.
53. Suvisaari J., Brache V., Nieschlag E., et al. Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum Reprod 1997, 12:967-973.
54. Brown T.R. Nonsteroidal selective androgen receptors modulators (SARMs): designer androgens with flexible structures provide clinical promise. Endocrinology 2004, 145:5417-5419.
55. Raichle M.E., Gusnard D.A. Appraising the brain's energy budget. Proc Natl Acad Sci USA 2002, 99:10237-10239.
56. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
57. Mosconi L., De Santi S., Li J., et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2008, 29:676-692.
58. Martins I.J., Hone E., Foster J.K., et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006, 11(8):721-736.
59. Liang W.S., Dunckley T., Beach T.G., et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics 2008, 33:240-256.
60. Liang W.S., Reiman E.M., Valla J., et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA 2008, 105:4441-4446.
61. Blalock E.M., Geddes J.W., Chen K.C., et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 2003, 23:3807-3819.
62. Blalock E.M., Geddes J.W., Chen K.C., et al. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 2004, 101(7):2173-2178.
63. Reiman E.M., Chen K., Alexander G.E., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004, 101:284-289.
64. Rowe W.B., Blacock E.M., Chen K-C., et al. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci 2007, 27:3098-3110.
65. Moreira P.I., Santos M.S., Seica R., et al. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007, 257:206-214.
66. Miller J.A., Oldham M., Geschwind D., et al. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci 2008, 28(6):1410-1420.
67. Mosconi L., Brys M., Switalski R., et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007, 104(48):19067-19072.
68. Reiman E.M., Caselli R.J., Alexander G.E., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98:3334-3339.
69. Ishii K., Minoshima S. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease - for. Eur J Nucl Med Mol Imaging 2005, 32:1463-1465.
70. Blass J.P. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann NY Acad Sci 2000, 924:170-183.
71. Nilsen J., Irwin R.W., Gallaher T.K., et al. Estradiol in vivo regulation of brain mitochondrial proteome. J Neurosci 2007, 27(51):14069-14077.
72. Resnick S.M., Gottlieb G.L., Gur R.E., et al. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998, 34:171-182.
73. Maki P.M., Resnick S.M. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000, 21:373-383.
74. Rasgon N.L., Silverman D., Siddarth P., et al. Estrogen use and brain metabolic change in postmenopausal women. Neurobiol Aging 2005, 26:229-235.
75. Janssen I., Powell L.H., Crawford S., et al. Menopause and the metabolic syndrome: the study of women's health across the nation. Arch Intern Med 2008, 168:1568-1575.
76. Pitteloud N., Mootha V.K., Dwyer A.A., et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28(7):1636-1642.